HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Contractor, K. B. Articles by Aboagye, E. O. Search for Related Content PubMed PubMed Citation Articles by Contractor, K. B. Articles by Aboagye, E. O.

Monitoring Predominantly Cytostatic Treatment Response with ¹⁸F-FDG PET

Department of Oncology, Imperial College London, London, United Kingdom

Correspondence: For correspondence or reprints contact: Eric O. Aboagye, Room 240, MRC Cyclotron Bldg., Clinical Sciences Centre, Imperial College London, London W12 0NN, United Kingdom. E-mail: eric.aboagye{at}imperial.ac.uk

¹⁸F-FDG PET and, more recently, PET/CT have been established as response biomarkers for monitoring cytotoxic or cytoreductive cancer therapies. With the advent of targeted cancer therapies, which are predominantly cytostatic, ¹⁸F-FDG PET is increasingly being used to monitor the therapeutic response to these agents as well. The impressive outcome of ¹⁸F-FDG PET studies in patients with gastrointestinal stromal tumors treated with imatinib mesylate brought to the forefront the use of this biomarker for assessing the response to targeted therapies. The use of ¹⁸F-FDG PET for this purpose has practical challenges, including quantitative analysis and timing of scans. This review provides a summary of clinical studies of targeted therapies done to date with ¹⁸F-FDG PET and provides guidance on practical issues to ensure the optimal interpretation of imaging data in drug development and for patient care.

Key Words: ¹⁸F-FDG PET • cytostatic treatment • cytoreductive therapy • response monitoring • imatinib mesylate

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

This article has been cited by other articles:

				W. A. Weber Assessing Tumor Response to Therapy J. Nucl. Med., May 1, 2009; 50(Suppl_1): 1S - 10S. [Abstract] [Full Text] [PDF]